(2R,4S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(dimethylamino)-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide;hydrochloride | 578710-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2R,4S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-(dimethylamino)-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide;hydrochloride
• CAS: 578710-95-9
• 化学式: C₂₆H₃₀F₇N₃O*ClH
• 分子量: 569.993
• InChiKey: IEKOGKHGVZRKKQ-AAOMYUJBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.47
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.8
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1472222A1

  公开（公告）日：2004-11-03
• Novel Method
  申请人：Ferrari Giulio

  公开号：US20140128395A1

  公开（公告）日：2014-05-08

  There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
• US9782397B2
  申请人：——

  公开号：US9782397B2

  公开（公告）日：2017-10-10
• [EN] PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES<br/>[FR] DERIVES PIPERIDYLCARBOXAMIDE, ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES DONT LA MEDIATION EST ASSUREE PAR LES TACHYKININES
  申请人：GLAXO GROUP LTD

  公开号：WO2003066589A1

  公开（公告）日：2003-08-14

  The present invention relates to piperidine derivatives of formula (I) wherein R represents halogen or C1-4 alkyl; R1 represents hydrogen or C1-4 alkyl; R2 represents hydrogen , C1-4 alkyl or R2 together with R3 represents C3-7 cycloalkyl; R3 represents hydrogen, C1-4 alkyl, C3-7 cycloalkyl or C3-6 alkenyl; or R1 and R3 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group; R4 represents trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, trifluoromethoxy or halogen; R is hydrogen and R is NR7R8 or R5 is NR8R9 and R6 is hydrogen; R7 represents hydrogen or C1-4 alkyl or R7 and R8 together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen; R8 represents hydrogen, phenyl, C3-7 cycloalkyl, (CH2)pC(O)NR10R11, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C1-4 alkyl, S(O)2C1-4 alkyl or C(O) C1-4 alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C1-4 alkyl S(O)2C1-4 alkyl or C(O) C1-4 alkyl or R8 represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C1-4 alkyl, S(O)2C1-4 alkyl or C(O) C1-4 alkyl; or R8 is a C1-6 alkyl group optionally substituted by one or two groups selected from fluorine, phenyl(optionally substituted by C1-4 alkyl, C(O) C1-4 alkyl or halogen), =O, C3-7 cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C1-4 alkoxy or trifluoromethyl; R9 is hydrogen, C1-4 alkyl or R9 and R8 together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C1-4 alkyl, =O, S(O)2C1-4 alkyl, C(O) C3-7 cycloalkyl or C(O) C1-4 alkyl; R10 and R11 are independently hydrogen or C1-4 alkyl group; X represents a nitrogen atom and Y is CH or X represents CH and Y is nitrogen;m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof; the process for their preparation and their use in the treatment of conditions mediated by tachykinins.